Double cortin-like kinase 1 (DCLK1) exhibits high expression levels across various cancers, notably in human colorectal cancer (CRC). Diacerein, a clinically approved interleukin (IL)-1β inhibitor for osteoarthritis treatment, was evaluated for its impact on CRC proliferation and migration, alongside its underlying mechanisms, through both in vitro and in vivo analyses. The study employed MTT assay, colony formation, wound healing, transwell assays, flow cytometry, and Hoechst 33342 staining to assess cell proliferation, migration, and apoptosis. Additionally, proteome microarray assay and western blotting analyses were conducted to elucidate diacerein’s specific mechanism of action. Our findings indicate that diacerein significantly inhibits DCLK1-dependent CRC growth in vitro and in vivo. Through high-throughput proteomics microarray and molecular docking studies, we identified that diacerein directly interacts with DCLK1. Mechanistically, the suppression of p-STAT3 expression following DCLK1 inhibition by diacerein or specific DCLK1 siRNA was observed. Furthermore, diacerein effectively disrupted the DCLK1/STAT3 signaling pathway and its downstream targets, including MCL-1, VEGF, and survivin, thereby inhibiting CRC progression in a mouse model, thereby inhibiting CRC progression in a mouse model.
| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Park SY, Kim JY, Choi JH, et al. Inhibition of lEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness[J]. Clin Cancer Res, 2019, 25(4): 1415-1429.
|
| [3] |
Nakanishi Y, Seno H, Fukuoka A, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine[J]. Nat Genet, 2013, 45(1): 98-103.
|
| [4] |
Qiu W, Remotti HE, Tang SM, et al. Pancreatic DCLK1+ cells originate distinctly from PDX1+ progenitors and contribute to the initiation of intraductal papillary mucinous neoplasm in mice[J]. Cancer Lett, 2018, 423: 71-79.
|
| [5] |
Gzil A, Szylberg Ł, Jaworski D, et al. The essential role of DCLK1 in pathogenesis, diagnostic procedures and prognostic stratification of colorectal cancer[J]. Anticancer Res, 2019, 39(6): 2689-2697.
|
| [6] |
Nguyen CB, Kotturi H, Waris G, et al. (Z)-3,5,4'-Trimethoxystilbene limits hepatitis C and cancer pathophysiology by blocking microtubule dynamics and cell-cycle progression[J]. Cancer Res, 2016, 76(16): 4887-4896.
|
| [7] |
Bharti R, Dey G, Ojha PK, et al. Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer[J]. Oncogene, 2016, 35(30): 3965-3975.
|
| [8] |
Chandrakesan P, Yao J, Qu D, et al. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells[J]. Mol Cancer, 2017, 16(1): 30.
|
| [9] |
Patel O, Dai W, Mentzel M, et al. Biochemical and structural insights into doublecortin-like kinase domain 1[J]. Structure, 2016, 24(9): 1550-1561.
|
| [10] |
Weygant N, Qu D, Berry WL, et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1[J]. Mol Cancer, 2014, 13: 103.
|
| [11] |
Sureban SM, May R, Weygant N, et al. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism[J]. Cancer Lett, 2014, 351(1): 151-161.
|
| [12] |
Galkin AV, Melnick JS, Kim S, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK[J]. Proc Natl Acad Sci USA, 2007, 104(1): 270-275.
|
| [13] |
Johnson DE, O'keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer[J]. Nat Rev Clin Oncol, 2018, 15(4): 234-248.
|
| [14] |
Bharti R, Dey G, Banerjee I, et al. Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy[J]. Cancer Lett, 2017, 388: 292-302.
|
| [15] |
Yang L, Yao Y, Bai Y, et al. Effect of the isoflavone corylin from Cullen corylifolium on colorectal cancer growth, by targeting the STAT3 signaling pathway[J]. Phytomedicine, 2021, 80: 153366.
|
| [16] |
Yang L, Zhou F, Zhuang Y, et al. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway[J]. Br J Cancer, 2021, 124(3): 645-657.
|
| [17] |
Yang L, Lin S, Kang Y, et al. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 31.
|
| [18] |
Fidelix TS, Macedo CR, Maxwell LJ, et al. Diacerein for osteoarthritis[J]. Cochrane Database Syst Rev, 2014, (2): CD005117.
|
| [19] |
Yang L, Li J, Xu L, et al. Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway[J]. Cancer Manag Res, 2019, 11: 1167-1176.
|
| [20] |
Eltobshi AA, Mohamed EA, Abdelghani GM, et al. Self-nanoemulsifying drug-delivery systems for potentiated anti-inflammatory activity of diacerein[J]. Int J Nanomedicine, 2018, 13: 6585-6602.
|
Funding
National Natural Science Foundation of China(82173856)
National Natural Science Foundation of China(82203322)
Natural Science Foundation of Zhejiang Province(LY21H300005)
Natural Science Foundation of Zhejiang Province(LGF22H030014)
Wenzhou Municipal Science and Technology Bureau(ZY2020025)
Wenzhou Municipal Science and Technology Bureau(H20210009)
Science and Technology Innovation Activity Plan for College Students of Zhejiang Province(2019R413012)
PDF
(2134KB)
